On the flip side, ARK’s ARKG ETF parted with a significant stake in Adaptive Biotechnologies Corp (NASDAQ: ADPT ), selling 278,792 shares worth roughly $2.65 million. This sale continues a trend from ...

Antibody drugs that target the PD-1 and VEGF pathways are in the ASCO spotlight, while doctors wrestle with how to use a new ...

Helmholtz Munich and the University of Sydney have identified biological mechanisms that are shared across psychiatric ...

The genetic makeup and structure of glioblastoma tumors can shift dramatically across different regions of a single tumor, ...

Ochre Bio appoints ex- Eli Lilly and AstraZeneca VP as Non-Executive DirectorThe appointment and ongoing science team expansion will help the company advance late-stage liver disease therapeutics29th ...

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

Veteran biopharma executive, Michael P. Cooke, PhD, joins Stratus to accelerate development of its pioneering Stratus Prime™ hematopoietic stem cell platformCAMBRIDGE, Mass., June 02, 2025 (GLOBE ...

A new project, co-led by Dr Joshua James and Professor Patrick Cai of the Manchester Institute of Biotechnology at The ...

A new project, co-led by Dr Joshua James and Professor Patrick Cai of the Manchester Institute of Biotechnology at The ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

Bristol Myers Squibb is partnering with BioNTech on a closely watched cancer drug, in a deal worth billions of dollars.